| name | es-cushing-screening-tests-for-hypercortisolism-recurrence |
| description | This skill recommends using biochemical tests to screen for hypercortisolism to detect recurrence in patients with ACTH-dependent Cushing's syndrome after surgical remission. It is triggered during postoperative follow-up when the HPA axis has recovered, annually, or sooner if clinical signs of hypercortisolism (e.g., weight gain, hypertension, glucose intolerance) or abnormal late-night salivary cortisol/UFC appear. |
Using Tests to Screen for Hypercortisolism to Assess for Recurrence in ACTH-Dependent Cushing's Syndrome
STEP 1 — Gather Information
Collect postoperative timing, HPA axis recovery status, symptoms (weight gain, hypertension, glucose intolerance, fatigue, mood changes), prior biochemical remission values, and imaging if available. Obtain late-night salivary cortisol, urine free cortisol (UFC), or low-dose dexamethasone suppression test per local protocol.
STEP 2 — Rule In / Rule Out
Is there a clinical suspicion of recurrence (new/significant symptoms) OR an abnormal screening test (late-night salivary cortisol > upper limit of normal, UFC > 2× ULN, or failure to suppress cortisol with dexamethasone)?
- Yes: Proceed to confirmatory testing.
- No: Continue routine surveillance (clinical assessment annually and biochemical testing every 6–12 months).
STEP 3 — Classify or Stratify
If screening test is abnormal, repeat the same test under standardized conditions (avoid stress, illness, medication interference).
- Repeat normal: Consider false positive; maintain routine surveillance.
- Repeat abnormal: Proceed to definitive evaluation (pituitary MRI, petrosal sinus sampling if ACTH-dependent source uncertain, or adrenal imaging if adrenal source suspected).
STEP 4 — Decide
If imaging confirms a lesion suggestive of recurrent ACTH source: discuss repeat transsphenoidal surgery, radiation therapy, medical therapy, or bilateral adrenalectomy based on lesion resectability, patient preference, and comorbidities.
If no lesion identified but biochemical evidence persists: consider empirical medical therapy (steroidogenesis inhibitor) or repeat imaging in 3–6 months.
Clinical Guardrails / Mimics / Pitfalls
Do not diagnose recurrence on a single abnormal test without confirmation due to assay variability, stress, or medication effects. Avoid overtreatment of borderline results; ensure HPA axis has recovered before interpreting cortisol levels. Do not neglect subtle symptoms (e.g., mild weight gain) as they may precede biochemical relapse.
Concrete Clinical Example
A 42‑year‑old woman with ACTH‑dependent Cushing’s disease underwent transsphenoidal surgery; 14 months postoperatively she reported 5 kg weight gain and new‑onset hypertension. Late‑night salivary cortisol was 1.8× ULN; repeat test remained elevated. Pituitary MRI showed a 6 mm enhancing lesion. She opted for repeat transsphenoidal surgery, achieving postoperative UFC < ULN and symptom resolution.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818
